Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major

Haematologica

Volumn 91, Issue 10, 2006, Pages 1343-1351

  Galanello, Renzo ^a   Piga, Antonio ^b   Forni, Gian Luca ^c   Bertrand, Yves ^d   Foschini, Maria Loreta ^a   Bordone, Elena ^b   Leoni, Giovanbattista ^a   Lavagetto, Antonella ^c   Zappu, Antonietta ^a   Longo, Filomena ^b   Maseruka, Henry ^e   Latham, Nicola ^e   Sechaud, Romain ^e   Belleli, Rossella ^e   Alberti, Daniele ^e  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d HÔPITAL DEBROUSSE   (France)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Deferasirox; ICL670; Iron chelation; Pediatric; Thalassemia

Indexed keywords

AMINOTRANSFERASE; DEFERASIROX; FERRITIN; IRON; IRON CHELATING AGENT; IRON COMPLEX;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEADACHE; HUMAN; INFLUENZA; IRON INTAKE; MALE; NAUSEA; PATIENT COMPLIANCE; PHARYNGITIS; RASH; RHINITIS; THALASSEMIA MAJOR; TONSILLITIS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; TRIAZOLES;

EID: 33749991316     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Olivieri NF. The b-thalassemias. N Engl J Med 1999;341:99-109.
2. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
3. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol 2002;76:219-28.
4. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol 2002; 509:91-125.
5. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
6. Modell B, Khan M, Darlison M. Survival in b-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
7. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
8. Heinz U, Hegetschweiler K, Acklin P, Faller B, Lattmann R, Schnebli HP. 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selective iron(iii) complexing agent. Angew Chem Int Ed Engl 1999;38: 2568-70.
9. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-76.
10. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002;509: 185-203.
11. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
12. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to b-thalassemia. J Clin Pharmacol 2003;43:565-72.
13. Piga A, Galanello R, Cappellini MD, Forni G, Opitz H, Ford JM et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002;100 Suppl 11:5a[abstract].
14. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571-90.
15. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966;41:613-35.
16. Tanner JM, Healy MJR, Goldstein H, Cameron N. Assessment of skeletal maturity and prediction of adult height (TWZ method). Third ed. London: WB Saunders. 2001.
17. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
18. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
19. Lenter C, ed. Geigy Scientific Tables. Volume 1, 8th Ed., 1981; 220.
20. Crisponi G, Nurchi VM, Silvagna R, Lubinu G, Ambu R, Marras A, et al. Critical-evaluation of analytical procedures for trace-element determination in human liver using ICP-OES. Atomic Spectroscopy 1995;16:73-8.
21. Fischer R, Engelhardt R, Gabbe EE, Heinrich HC, Schmiegel WH, Wurbs D. Liver iron quantification in the diagnosis and therapeutic control of iron loaded patients. In: Hoke M, Erne SN, Okada YC, Romani GL, eds. Biomagnetism: clinical aspects. Amsterdam: Elsevier 1992. p. 585-8.
22. Piga, A. Comparison of LIC Obtained from Biopsy, BLS and R2-MRI in iron overloaded patients with b-thalassemia, treated with Deferasirox (Exjade®, ICL670). Blood 2005;106[abstract 2689].
23. Ropert-Bouchet M, Turlin B, Graham G, Rabault R, Le Treut A, Brissot P, et al. Drying methods affect the wet: dry weight ratio of liver tissue samples and impact liver iron content measurements. Prague 2005;[abstract P274].
24. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 2005;107:3455-62.